An Antidote For The Incumbent’s Curse


Jamie Smith

Magnus interviewed for feature article in the Davos edition of The Innovator.

"Corporations in just about every industry are struggling with how to innovate. Culture clash with startups, a not-invented-here attitude and fear of anything that might change traditional business models and impact quarterly results are some of the reasons why large, incumbent firms rarely introduce radical product innovations.

The phenomenon is sometimes referred to as “the incumbent’s curse.” And the pharmaceutical industry, and life science in general, face additional challenges due to complex and uncertain development processes, regulatory issues, long lead times, large investments, huge financial risks, and high failure rates."

Click here to read the full article.